Rockwell Automation (NYSE: ROK) delivered a strong third quarter of fiscal 2026, with organic sales rising 10% and adjusted earnings per share (EPS) increasing more than 20% year-over-year. The industrial automation giant exceeded expectations as demand in semiconductor, data center, and e-commerce sectors offset softer capital spending in food and beverage industries.

Reported sales grew 8%, while the enterprise operating margin expanded to 22.3%, reflecting a 280 basis point improvement from the prior year. This performance underscores the company's disciplined execution and favorable product mix, despite persistent inflationary pressures on component costs.

Segment Performance Highlights

The company’s three operating segments displayed divergent trends, driven by varying end-market dynamics:

Intelligent Devices benefited from broad-based growth across product lines, including Point I/O and PowerFlex drives. Software & Control saw significant margin expansion due to strong volume in Logix controllers. Conversely, Lifecycle Services revenue declined slightly, constrained by delayed capital projects in traditional process industries.

Regional and Vertical Trends

North America remained the strongest region, posting 12% year-over-year growth. The company highlighted robust activity in high-growth verticals:

• E-commerce and warehouse automation: Sales up 30%.
• Semiconductor: Strong double-digit growth driven by AI infrastructure investments.
• Data center: Continued strength in power, cooling, and control systems.
• Life sciences: Sales up 10%, aided by GLP-1 related manufacturing expansions.

While large greenfield projects remain cautious, modernization spending continues to drive results. Blake Moret, Chairman and CEO, noted that excluding data center-related revenue, organic growth would still have been 8%, indicating broad-based health across the portfolio.

Guidance Update

Rockwell Automation raised its fiscal 2026 outlook, citing outperformance in Q3 and improved visibility for Q4.

• Full-year sales growth: Now expected between 7.5% and 9.5% (previously lower).
• Adjusted EPS: Guided to $13.15 at the midpoint, representing approximately 25% growth versus fiscal 2025.
• Enterprise operating margin: Expected to reach 21.5%, up 260 basis points year-over-year.
• Free cash flow conversion: Targeted at 100% for the fiscal year.

What the Numbers Show

A key divergence emerges between top-line momentum and recurring revenue metrics. While total organic sales grew 10%, annual recurring revenue (ARR) grew only 6%, below management's expectations. This gap highlights a dependency on one-time hardware sales and project-based software wins rather than steady subscription-based services. The slower ARR growth, particularly in Lifecycle Services, suggests that customers are prioritizing immediate productivity tools over long-term service contracts amidst economic uncertainty.

Management acknowledged that inflation remains a headwind, particularly affecting memory costs in the Software & Control segment. However, pricing actions and productivity initiatives are expected to maintain positive price-cost dynamics for the remainder of the fiscal year.

PBS Biotech has embedded Rockwell Automation technology into its MiniPRO™ multi-parallel bioreactor platform. This integration aims to accelerate cell therapy process development and simplify the transition from laboratory research to commercial manufacturing.

The partnership addresses critical bottlenecks in Advanced Therapeutic Medicinal Products (ATMP) development. Industry workflows often suffer from low throughput, manual processes, and non-standardized environments. These factors introduce variability and increase risk as therapies advance toward commercialization.

Standardizing process control

The MiniPRO™ platform features up to 24 independently controlled bioreactors that enable parallel process development. By utilizing Rockwell’s FactoryTalk® software and Process Library, the system delivers integrated, real-time process control within a scalable environment. This setup allows for seamless integration into a larger PlantPAx® distributed control system (DCS), which is used to automate entire cell-therapy facilities.

Sharon Harvey, director of product management and strategy at PBS Biotech, stated that Rockwell technologies provide industrial-grade control of critical process parameters. This ensures users generate high-quality data in an environment that mirrors commercial manufacturing conditions.

Enhancing scalability and integration

The Advanced Regenerative Manufacturing Institute (ARMI), a nonprofit advancing the US bioeconomy, adopted the platform early. Tom Bollenbach, chief technology officer at ARMI, noted that industrial-grade control is rare in systems as small as the MiniPRO. He highlighted that standard controls streamline system integration, allowing supervisory systems to communicate easily with subsystems. This capability enables the construction of larger manufacturing lines with sequential hand-offs between processes.

PBS Biotech demonstrated that process performance on the MiniPRO is consistent with its larger-scale Vertical-Wheel® bioreactors. This continuity supports more predictable transfers into Good Manufacturing Practice (GMP) settings.

Strategic implications for cell therapy

The collaboration underscores a shift toward industrializing early-stage development. By introducing widely used automation platforms during the development phase, teams can preserve process knowledge and control as they progress toward clinical and commercial stages.

Matt Weaver, vice president of global industry life sciences at Rockwell Automation, emphasized that seamless tech transfers reduce risk during scale-up. The use of standardized automation helps mitigate the variability often seen in proprietary or PC-based systems.